...
首页> 外文期刊>Journal of drug targeting >In vivo evaluation of guar gum-based colon-targeted drug delivery systems of ornidazole in healthy human volunteers.
【24h】

In vivo evaluation of guar gum-based colon-targeted drug delivery systems of ornidazole in healthy human volunteers.

机译:在健康人类志愿者中对奥硝唑基于瓜尔胶的结肠靶向结肠给药系统进行体内评估。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to find the in vivo performance of guar gum-based colon-targeted tablets of ornidazole (dose 250 mg) in comparison with an immediate release tablet of ornidazole (250 mg) in human volunteers. Six healthy volunteers participated in the study, and a cross over design was followed. The plasma concentration of ornidazole was estimated by HPLC. The immediate release tablets of ornidazole produced peak plasma concentration (Cmax of 2171.33+/-278.15 ng/ml) at 2.91+/-0.14 h (Tmax) whereas colon-targeted tablets produced peak plasma concentration (Cmax of 1716.66+/-125.83 ng/ml) at 11.91+/-0.14 h. The delayed Tmax, decreased Cmax, and decreased ka of ornidazole from guar gum-based colon-targeted ornidazole tablets, in comparison with the immediate tablets, indicated that the drug was not released in stomach and small intestine, but targeted to colon. Slow absorption of ornidazole from the less absorptive colon might result in the availability of drug for local action in the colon.
机译:本研究的目的是在人类志愿者中发现基于瓜尔豆胶的结肠靶向奥硝唑片(剂量250 mg)与奥硝唑即释片剂(250 mg)的体内性能。六名健康志愿者参加了研究,并进行了交叉设计。奥硝唑的血浆浓度通过HPLC估算。奥硝唑的速释片在2.91 +/- 0.14 h(Tmax)时产生峰值血浆浓度(Cmax为2171.33 +/- 278.15 ng / ml),而结肠靶向片剂产生的峰值血浆浓度(Cmax为1716.66 +/- 125.83 ng / ml)在11.91 +/- 0.14 h。与立即片剂相比,瓜尔胶基结肠靶向奥硝唑片剂中奥硝唑的延迟Tmax降低,Cmax降低和ka降低,表明该药物未在胃和小肠中释放,而是靶向结肠。从吸收性较差的结肠中缓慢吸收奥硝唑可能会导致药物在结肠中的局部作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号